Mounjaro weight loss injection reviews and NHS access: what the evidence shows

What the reviews and trial data are actually telling you

There is a widespread assumption that glowing Mounjaro reviews online are mostly hype, written by people who had unusually good results. It is worth laying that idea down gently, because the controlled trial evidence is, on its own, genuinely striking. In SURMOUNT-1, which enrolled 2,539 adults with obesity who did not have type 2 diabetes, participants taking 15mg tirzepatide lost an average of around 20–21% of their body weight over 72 weeks alongside a reduced-calorie diet and increased activity. That figure comes from a peer-reviewed paper in the New England Journal of Medicine, not a forum post.

Individual responses vary. Some people lose more, some less, and a small number find the side effects difficult enough to discontinue. The most commonly reported effects are gastrointestinal (nausea, loose stools, constipation, indigestion) and tend to be most noticeable at the start of treatment or after a dose step up. For most people they settle within a couple of weeks. A prescriber discusses all of this at the point of assessment, because the decision to start any prescription medicine belongs in a clinical conversation, not in a comment thread.

NICE reviewed this evidence and in December 2024 recommended tirzepatide for NHS use in adults with a BMI of 35 or above and at least one weight-related health condition, lower thresholds apply for some ethnic backgrounds under NICE's appraisal (TA1026). That recommendation set the framework for the phased NHS rollout described below.

How NHS access to Mounjaro actually works right now

The NHS rollout of tirzepatide is real, and it is moving, but it is phased deliberately, and the eligibility criteria at each stage are specific. Understanding how the NHS tirzepatide pathway works saves a lot of frustration.

From June 2025, the first cohort opened: adults with a BMI of 40 or above who also have four or more of five defined health conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease or type 2 diabetes). A second cohort, covering BMI 35–39.9 with four or more of those conditions, activated in June 2026. A further expansion to BMI 40-plus with three conditions is expected around March 2027. These thresholds are 2.5 kg/m² lower for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds.

GP practices may now prescribe under the 2026/27 contract, but participation varies by practice and region. Meeting the criteria on paper does not mean an immediate appointment or a guaranteed prescription. Every NHS patient is also required to take part in structured diet and activity support as part of treatment. If you want to understand whether you currently sit within an active NHS cohort, the Mounjaro NHS eligibility detail page walks through each phase clearly.

What a private prescription route involves, and who it suits

For adults who are clinically eligible for tirzepatide but sit outside the current NHS cohorts (or who want to start without waiting for GP capacity to catch up) a private prescription through a GPhC-registered pharmacy is the regulated alternative. This is not a shortcut around clinical assessment; it is a different route to the same standard of prescription-only oversight.

At nume, a real prescriber (a GPhC-registered Independent Prescriber, not automated software) reads your consultation the same day. Photo ID verification and live weight confirmation are part of that process, alongside a check of your medical history for contraindications. Medicines are sourced through the licensed UK supply chain. Details of what the service includes, and current treatment pricing, are on the Mounjaro treatment page. There are no subscriptions and no hidden fees; every repeat order is clinically re-reviewed before it is dispensed.

For context on how private costs compare and what a transparent price should include, the weight loss treatment overview covers the landscape without promotional pressure. Worth reading before committing anywhere.

Who is not a candidate, and what responsible prescribing looks like

Mounjaro is not suitable for everyone who wants to lose weight. It is not licensed for people under 18. It is not recommended during pregnancy, whilst breastfeeding, or when actively trying to conceive. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take it. A history of pancreatitis, certain gastrointestinal conditions, or specific medicines already in use can also affect suitability, which is precisely why the prescriber's assessment exists.

If you are currently taking an oral contraceptive, there is something worth knowing: clinical guidance suggests adding a non-oral method of contraception for the first four weeks of tirzepatide and for four weeks after each dose increase, because absorption of the pill may be reduced. This is the kind of detail that belongs in a prescriber conversation, not a review thread. NHS England's guidance on weight management injections covers this alongside advice about HRT and surgical procedures.

The patient experience and UK review context page goes into more depth on what people commonly report in the first weeks of treatment, and if you are weighing up what NHS Mounjaro patients say about their results, that page brings together honest accounts alongside the clinical context you need to interpret them. If you have read enough and want to see whether you are clinically suitable, check your eligibility with our prescribers, the consultation is free, and there is no obligation. It is also worth understanding how NHS weight loss injections with Mounjaro are accessed in practice, particularly if you are unsure which route applies to your situation.